A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Incyte Corporation
Incyte Corporation
Incyte Corporation
Incyte Corporation
Prelude Therapeutics
Incyte Corporation
Disc Medicine, Inc
Novartis
iOMEDICO AG
Celgene
Massive Bio, Inc.
PharmaEssentia
Cogent Biosciences, Inc.
Cellenkos, Inc.
PharmaEssentia Japan K.K.